Steve V Edelman

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Multisite evaluation of a new diabetes self-test for glucose and glycated protein (fructosamine)
    S V Edelman
    University of California at San Diego Veterans Administration Medical Center 92161, USA
    Diabetes Technol Ther 2:233-8. 2000
  2. ncbi Strategies for insulin therapy in type 2 diabetes
    Steven V Edelman
    Division of Diabetes and Metabolism, San Diego Veterans Affairs Medical Center, 3350 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    South Med J 98:363-71. 2005
  3. ncbi Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
    Steve V Edelman
    VA San Diego Healthcare Center, Department of Endocrinology and Metabolism, 3350 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    Nat Clin Pract Endocrinol Metab 3:E1; discussion E2. 2007
  4. ncbi Pramlintide in the treatment of diabetes
    S V Edelman
    Division of Diabetes and Metabolism, San Diego Veterans Affairs Medical Center, San Diego, CA 92161, USA
    Int J Clin Pract 60:1647-53. 2006
  5. ncbi Amylin replacement therapy in patients with type 1 diabetes
    Steven V Edelman
    University of California, San Diego, Veterans Affairs Medical Center, 3550 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    Diabetes Educ 32:119S-127S. 2006
  6. ncbi Pramlintide in the treatment of diabetes mellitus
    Steve Edelman
    Division of Diabetes Metabolism, VA San Diego Healthcare Center, San Diego, California 92161, USA
    BioDrugs 22:375-86. 2008
  7. ncbi Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone
    Steven V Edelman
    Veterans Affairs Health Care Systems, V111G Endocrinology, University of California San Diego, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Diabetes Technol Ther 4:175-89. 2002
  8. ncbi Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem
    William H Polonsky
    Department of Psychiatry, University of California, San Diego, USA
    Diabetes Care 28:2543-5. 2005
  9. ncbi Osteoporosis and diabetes
    Diane L Chau
    Department of Geriatric Medicine, VA Sierra Health Care Systems, University of Nevada School of Medicine, 1000 Locust Street, MS 018, Reno, NV 89502, USA
    Curr Diab Rep 3:37-42. 2003
  10. ncbi Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostasis
    Davida F Kruger
    Henry Ford Health System, Division of Endocrinology and Metabolism, 3031 West Grand Boulevard, Suite 800, Detroit, MI 48202, USA
    Diabetes Educ 33:32S-46S; quiz 47S-48S. 2007

Collaborators

Detail Information

Publications27

  1. ncbi Multisite evaluation of a new diabetes self-test for glucose and glycated protein (fructosamine)
    S V Edelman
    University of California at San Diego Veterans Administration Medical Center 92161, USA
    Diabetes Technol Ther 2:233-8. 2000
    ..This new self-testing system has the potential to improve glycemic control dramatically in patients with diabetes, including those patients with type 2 diabetes using oral drug therapy...
  2. ncbi Strategies for insulin therapy in type 2 diabetes
    Steven V Edelman
    Division of Diabetes and Metabolism, San Diego Veterans Affairs Medical Center, 3350 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    South Med J 98:363-71. 2005
    ....
  3. ncbi Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
    Steve V Edelman
    VA San Diego Healthcare Center, Department of Endocrinology and Metabolism, 3350 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    Nat Clin Pract Endocrinol Metab 3:E1; discussion E2. 2007
  4. ncbi Pramlintide in the treatment of diabetes
    S V Edelman
    Division of Diabetes and Metabolism, San Diego Veterans Affairs Medical Center, San Diego, CA 92161, USA
    Int J Clin Pract 60:1647-53. 2006
    ..Clinical Trial Registry Numbers: 137-155 open-label clinical trial: NCT00108004 (Pramlintide long-term, placebo-controlled clinical trials were completed prior to the requirement for NCT registry)...
  5. ncbi Amylin replacement therapy in patients with type 1 diabetes
    Steven V Edelman
    University of California, San Diego, Veterans Affairs Medical Center, 3550 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    Diabetes Educ 32:119S-127S. 2006
    ..This combination of benefits makes pramlintide an important therapeutic tool for improving the metabolic control and quality of life of people with type 1 diabetes...
  6. ncbi Pramlintide in the treatment of diabetes mellitus
    Steve Edelman
    Division of Diabetes Metabolism, VA San Diego Healthcare Center, San Diego, California 92161, USA
    BioDrugs 22:375-86. 2008
    ..These factors make pramlintide an attractive option for the treatment of postprandial hyperglycemia in patients with diabetes using mealtime insulin...
  7. ncbi Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone
    Steven V Edelman
    Veterans Affairs Health Care Systems, V111G Endocrinology, University of California San Diego, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Diabetes Technol Ther 4:175-89. 2002
    ....
  8. ncbi Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem
    William H Polonsky
    Department of Psychiatry, University of California, San Diego, USA
    Diabetes Care 28:2543-5. 2005
  9. ncbi Osteoporosis and diabetes
    Diane L Chau
    Department of Geriatric Medicine, VA Sierra Health Care Systems, University of Nevada School of Medicine, 1000 Locust Street, MS 018, Reno, NV 89502, USA
    Curr Diab Rep 3:37-42. 2003
    ..In patients who have positive risk factors for osteoporosis, or in those who present with fractures, evaluation of bone density should be done and respective preventive or therapeutic interventions should be applied...
  10. ncbi Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostasis
    Davida F Kruger
    Henry Ford Health System, Division of Endocrinology and Metabolism, 3031 West Grand Boulevard, Suite 800, Detroit, MI 48202, USA
    Diabetes Educ 33:32S-46S; quiz 47S-48S. 2007
  11. ncbi Incretins and their role in the management of diabetes
    Juan P Frias
    Animas Corp, West Chester, Pennsylvania 19380, USA
    Curr Opin Endocrinol Diabetes Obes 14:269-76. 2007
    ..To review data from clinical trials of incretin mimetics in patients with type 2 diabetes...
  12. ncbi Insulin therapy in type 2 diabetes
    Trent Davis
    Section of Diabetes/Metabolism, Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    Med Clin North Am 88:865-95, x. 2004
    ..The American Diabetes Association recommends that the objective of normalizing glycemia and glycosylated hemoglobin concentrations for patients with type 2 diabetes should be similar to that for type 1 diabetes...
  13. ncbi Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes
    Satish K Garg
    Department of Medicine and Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Diabetes Care 27:734-8. 2004
    ..The capability of emerging glucose sensor technology to continuously monitor glucose levels may provide ways to achieve glycemic targets while reducing hypoglycemia...
  14. ncbi The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia
    Charles Choe
    Division of Diabetes and Metabolism, San Diego Veterans Affairs Medical Center, and University of California, San Diego, California, USA
    South Med J 100:1123-31. 2007
    ..Periodic glucose profiles and regular SMBG will remain an important tool for both patients and healthcare professionals when using these newer approaches...
  15. ncbi Incretins: what does the future hold?
    Steven V Edelman
    University of California San Diego School of Medicine, San Diego, California 92161, USA
    Diabetes Technol Ther 7:809-12. 2005
  16. ncbi Optimizing diabetes treatment using an amylin analogue
    Steven V Edelman
    University of California San Diego, Veterans Affairs Medical Center, 3350 La Jolla Village Drive 111G, San Diego, CA 92161, USA
    Diabetes Educ 34:4S-10S. 2008
    ..This combination of benefits associated with pramlintide makes it an attractive treatment option for patients with either type 1 or type 2 diabetes...
  17. ncbi Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program
    Allan F Moore
    Center for Human Genetic Research, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Diabetes 57:2503-10. 2008
    ....
  18. ncbi Pharmacokinetics and glucodynamics of rapid-, short-, and intermediate-acting insulins: comparison of jet injection to needle syringe
    Mark J Sarno
    Diabetes Technol Ther 4:863-6. 2002
  19. ncbi Erectile dysfunction and diabetes
    Neelima V Chu
    VA Healthcare San Diego, 3350 La Jolla Village Drive, III G, San Diego, CA 92161, USA
    Curr Diab Rep 2:60-6. 2002
    ..Improved techniques in diagnoses and treatment of impotence have given the male with diabetes some hope in the management of this prevalent and emotionally disturbing complication...
  20. ncbi Gastrointestinal disturbances in diabetes
    Manju Chandran
    Division of Endocrinology and Metabolism, University of California School of Medicine, VA San Diego Health Care Systems, 3350 La Jolla Village Drive, Mail Code 111G, San Diego, CA 92161, USA
    Curr Diab Rep 3:43-8. 2003
    ..In addition to pharmacologic therapy, glycemic control and dietary manipulation play an important role in managing GI disorders in people with diabetes...
  21. ncbi Thiazolidinediones
    Steven V Edelman
    N Engl J Med 352:205-7; author reply 205-7. 2005
  22. ncbi Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes
    Theodore P Ciaraldi
    Veterans Affairs San Diego HealthCare System (111G, 3350 La Jolla Village Drive, San Diego, California 92161, USA
    J Clin Endocrinol Metab 90:352-8. 2005
    ....
  23. ncbi Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus
    Meenakshi A Bhalla
    Division of Cardiology, Veteran's Affairs Medical Center, San Diego, California 92161, USA
    J Am Coll Cardiol 44:1047-52. 2004
    ..There was a marked decrease in survival in the patient group with BNP >120 pg/ml. CONCLUSIONS: B-type natriuretic peptide appears to be a reliable predictor of future cardiac and all-cause mortality in diabetic patients...
  24. ncbi Pumps and type 2 diabetes. If you can improve your diabetes control, and if you can accommodate yourself to it, the pump might just be the best diabetes therapy for you
    Steven V Edelman
    Diabetes Forecast 55:62-5. 2002
  25. ncbi The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors
    Steven V Edelman
    Division of Endocrinology and Metabolism, University of California, San Diego, and Veterans Affairs Medical Center, San Diego, California, USA
    Rev Cardiovasc Med 4:S29-37. 2003
    ....
  26. ncbi Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker
    John B Buse
    Divisions of Endocrinology and of General Medicine and Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
    Diabetes Technol Ther 5:355-63. 2003
    ..The behavior of this analyte is different from all others used in the management of diabetes, creating potential opportunities for its use in clinical practice...
  27. ncbi Hypoglycemia unawareness and type 1 diabetes
    Steven V Edelman
    South Med J 97:1143-4. 2004